What they suggest is that measurement of neprilysin concentrations with an assay that appears reasonably specific holds prognostic importance. Specifically, this suggests that the neprilysin concentration in and of itself is an important prognostic factor.
Nonetheless, the ability to add measurements of neprilysin concentrations to ongoing research efforts may enrich our understanding of these mechanisms and allow us to better leverage this approach to help patients with HF. At present, the assay used is not one that would be easy to implement clinically, and although it adds prognostic significance, it remains unclear whether the incremental value is robust enough to warrant routine use. Furthermore, it would be of interest to assess neprilysin activity, because it is known that the convertases can change activity without a recognizable change in mass concentration (2) . In the interim, the proposition that neprilysin is important remains and suggests that for research studies, its inclusion in multivariate models that examine prognosis may be illuminating. The bigger hope is that future studies using serial samples will permit assessment of patient response to various treatments as part of efforts to improve our understanding of the basic mechanisms of neprilysin inhibition. In the long run, such understanding will allow further improvements in drug development based on this promising new therapy.
